Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Anebulo Pharmaceuticals Q2 2025 GAAP EPS $(0.09) Misses $(0.08) Estimate

Author: Benzinga Newsdesk | February 14, 2025 05:07pm
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 18.18 percent increase over losses of $(0.11) per share from the same period last year.

Posted In: ANEB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist